What's Available Now
A clinical guide to peptides for women in midlife, and why you probably haven't been offered any of them.
In July 2026, an FDA advisory committee voted to recommend six of seven peptides for the federal compounding list: BPC-157, TB-500, MOTS-c, KPV, Epitalon, and Semax. Wellness feeds called it a win. The fine print says otherwise.
What the vote actually means
The Pharmacy Compounding Advisory Committee is exactly what its name says: advisory. The FDA is not required to follow it. Even if the agency does, a full rulemaking process comes first: proposed rules, public comment, final action. No timeline has been announced. Regulatory attorneys following the docket estimate 2027 at the earliest.
Worth noting: FDA's own scientists recommended against all seven before the meeting, citing the near-total absence of human clinical data. The committee voted the other way, most margins 8–6. That's a close call on compounds with a thin evidence base, not a landslide.
- These are now legal to compound
- Your clinic can offer them next week
- The FDA will follow the recommendation
- The evidence base is settled
- A federal committee reviewed the science and found merit
- The regulatory direction has shifted
- Access may widen, in years rather than months
- Clinical networks were already ahead of it
Through vetted 503A compounding pharmacies and clinical provider networks, every peptide voted on in July, including the one the committee rejected, has been accessible to the right patient working with the right clinician. The vote didn't create that access. It acknowledged access that already existed.
The compounds, in plain language
These are the peptides most relevant to women in perimenopause, menopause, and post-menopause, and each is currently available through the RESOLVE clinical network. This is a working list, the eight I most often end up discussing with clients, and the reason each one comes up.
Nothing here is a recommendation. Whether any of it is appropriate for you depends entirely on your labs, your history, and clinical judgment.
Why you haven't been offered any of this
It exists. Most conventional providers simply aren't trained in it, aren't connected to compounding pharmacy networks, and aren't running the panels that would tell them where to look in the first place.
The model most women encounter is symptom management: a sleep aid for the sleep, an antidepressant for the mood, an orthopedic referral for the joints. Each symptom handled in isolation by a different specialist, none of them holding a map of what is happening underneath.
Perimenopause, menopause, and the years after are one continuous transition. It needs a systemic read, one that starts with data instead of guesswork.
Every recommendation starts with a comprehensive panel. Not the standard annual bloodwork, but the markers that actually show what is happening across hormones, metabolic function, inflammation, and cellular health. The plan is built from that data. Peptides are one instrument in it. So is HRT, strength training, sleep architecture, nutrition timing, and clinical monitoring over time.
The Precision Protocol is a 1:1 clinical coaching engagement built on that model: licensed medical team, 503A compounding pharmacy, biomarker-informed plans. Your relationship is with Sami. Not a portal, not a telehealth appointment with a stranger.
You're not declining.
You're uninvestigated.
If you've been told your labs are normal while feeling anything but, the next step takes about ten minutes.
Take the Scorecard Book a Free Call
